JP2021535149A5 - - Google Patents
Info
- Publication number
- JP2021535149A5 JP2021535149A5 JP2021510824A JP2021510824A JP2021535149A5 JP 2021535149 A5 JP2021535149 A5 JP 2021535149A5 JP 2021510824 A JP2021510824 A JP 2021510824A JP 2021510824 A JP2021510824 A JP 2021510824A JP 2021535149 A5 JP2021535149 A5 JP 2021535149A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- seq
- her2 bispecific
- pharmaceutical product
- system inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18191041.5 | 2018-08-27 | ||
| EP18191041 | 2018-08-27 | ||
| PCT/EP2019/072754 WO2020043683A1 (en) | 2018-08-27 | 2019-08-27 | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535149A JP2021535149A (ja) | 2021-12-16 |
| JP2021535149A5 true JP2021535149A5 (enExample) | 2022-08-12 |
| JP7459058B2 JP7459058B2 (ja) | 2024-04-01 |
Family
ID=63578931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510824A Active JP7459058B2 (ja) | 2018-08-27 | 2019-08-27 | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210246219A1 (enExample) |
| EP (1) | EP3843849A1 (enExample) |
| JP (1) | JP7459058B2 (enExample) |
| KR (1) | KR20210052468A (enExample) |
| CN (1) | CN112955221A (enExample) |
| AU (1) | AU2019328632A1 (enExample) |
| CA (1) | CA3106881A1 (enExample) |
| WO (1) | WO2020043683A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220168387A1 (en) * | 2019-03-29 | 2022-06-02 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| CN115151573A (zh) * | 2020-02-28 | 2022-10-04 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体、多特异性抗体及其用途 |
| WO2022058505A1 (en) * | 2020-09-18 | 2022-03-24 | Pieris Pharmaceuticals Gmbh | Biomarker methods and uses |
| WO2022158889A1 (en) * | 2021-01-25 | 2022-07-28 | Yuhan Corporation | Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody |
| CN117355319A (zh) | 2021-03-23 | 2024-01-05 | 皮里斯制药有限责任公司 | 用于癌症治疗的her2/4-1bb双特异性融合蛋白 |
| EP4469476A1 (en) * | 2022-01-25 | 2024-12-04 | Merus N.V. | Combination therapy for the treatment of cancer |
| CN116120461B (zh) * | 2022-04-29 | 2023-09-29 | 德琪(杭州)生物有限公司 | 新型抗药抗体以及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| KR101510065B1 (ko) | 2005-06-08 | 2015-04-07 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| RU2604814C2 (ru) | 2011-07-24 | 2016-12-10 | Кьюртек Лтд. | Варианты гуманизированных иммуномодулирующих моноклональных антител |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| JP6998646B2 (ja) | 2012-11-30 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| DK3049441T3 (da) | 2013-09-27 | 2020-02-03 | Hoffmann La Roche | Anti-PDL1-antistofformuleringer |
| AU2014339900B2 (en) | 2013-10-25 | 2019-10-24 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| SG10202002334PA (en) | 2013-12-17 | 2020-05-28 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| BR112017000497B1 (pt) | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| AU2016258977C1 (en) * | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| EP3309177B1 (en) | 2016-03-04 | 2020-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof |
-
2019
- 2019-08-27 AU AU2019328632A patent/AU2019328632A1/en not_active Abandoned
- 2019-08-27 WO PCT/EP2019/072754 patent/WO2020043683A1/en not_active Ceased
- 2019-08-27 CN CN201980071320.7A patent/CN112955221A/zh active Pending
- 2019-08-27 CA CA3106881A patent/CA3106881A1/en active Pending
- 2019-08-27 EP EP19756382.8A patent/EP3843849A1/en not_active Withdrawn
- 2019-08-27 US US17/271,149 patent/US20210246219A1/en not_active Abandoned
- 2019-08-27 JP JP2021510824A patent/JP7459058B2/ja active Active
- 2019-08-27 KR KR1020217007565A patent/KR20210052468A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| van de Donk et al. | T-cell-engaging bispecific antibodies in cancer | |
| Poletto et al. | Treatment strategies for patients with diffuse large B-cell lymphoma | |
| Choi et al. | T-cell agonists in cancer immunotherapy | |
| Ferris et al. | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation | |
| Vacchelli et al. | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| Cultrera et al. | Diffuse large B-cell lymphoma: current strategies and future directions | |
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2022532490A5 (enExample) | ||
| KR102115203B1 (ko) | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 | |
| JP2021525735A5 (enExample) | ||
| KR102786010B1 (ko) | 조합 및 이의 용도 | |
| JP2024505556A (ja) | がん、腫瘍および腫瘍細胞の局所および全身処置のための方法 | |
| Robak et al. | Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia | |
| JP2023536655A5 (enExample) | ||
| JP2024167261A (ja) | 抗原結合タンパク質 | |
| JP7158677B2 (ja) | 溶血性レンサ球菌の菌体を含む製剤との併用療法 | |
| WO2019177011A1 (ja) | 腫瘍免疫賦活剤 | |
| Lam et al. | Pharmacokinetics and pharmacodynamics of immunotherapy | |
| CA3214753A1 (en) | Dosing of bispecific t cell engager | |
| Forero-Torres et al. | Polatuzumab vedotin combined with obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (G-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Preliminary results of a phase Ib/II dose-escalation study | |
| US20240166747A1 (en) | Antigen binding proteins and combinations thereof | |
| Deligne et al. | The vaccinal effect of monoclonal antibodies in cancer therapy | |
| Guo et al. | immunomodulatory drugs in |